Subsidiary Bankruptcy and Deconsolidation (Details) - USD ($)			3 Months Ended		6 Months Ended
	Jul. 24, 2020	Apr. 26, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Aug. 07, 2020	Oct. 02, 2019	Jul. 02, 2019	Feb. 08, 2019	Feb. 05, 2019
Business Acquisition, Contingent Consideration [Line Items]
Gain (loss) on deconsolidation of subsidiary			$ 0	$ (167,000)	$ 0	$ (2,840,000)
Subsequent Event
Business Acquisition, Contingent Consideration [Line Items]
Bankruptcy claims, amount paid to settle claims	$ 800,000
DIP Credit Agreement | Debtor in Possession Credit and Security Facility
Business Acquisition, Contingent Consideration [Line Items]
Gain (loss) on deconsolidation of subsidiary					407,000
Payments for debtor in possession financing					407,000
Speciality Pharama
Business Acquisition, Contingent Consideration [Line Items]
Aggregate cash proceeds of intangible assets and remaining inventory		$ 250,000
Speciality Pharama | Internal Revenue Service (IRS)
Business Acquisition, Contingent Consideration [Line Items]
Bankruptcy claims, amount of filed claims likely to be denied			$ 1,937,000		$ 1,937,000			$ 9,302,000	$ 50,695,000
Speciality Pharama | Scenario, Forecast | Minimum
Business Acquisition, Contingent Consideration [Line Items]
Bankruptcy claims, amount paid to settle claims							$ 125,000
Speciality Pharama | DIP Credit Agreement | Debtor in Possession Credit and Security Facility
Business Acquisition, Contingent Consideration [Line Items]
DIP financing, amount arranged										$ 2,700,000
Serenity Pharmaceuticals, LLC | Subsequent Event
Business Acquisition, Contingent Consideration [Line Items]
Loss contingency, damages sought, value	3,096,000
Serenity Pharmaceuticals, LLC | Minimum | Subsequent Event
Business Acquisition, Contingent Consideration [Line Items]
Loss contingency, damages sought, value	$ 50,000,000
Specialty Pharma
Business Acquisition, Contingent Consideration [Line Items]
Equity method investments, fair value											$ 0